Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1978-4-17
|
pubmed:abstractText |
An effective influenza vaccine should be capable of providing protection against both the homologous virus strain and heterologous strains representing antigenic "drift". Two attenuated vaccines were evaluated, an A/Hong Kong/8/68 (H3N2) and an A/England/42/72 (H3N2) strain. Volunteers were immunized intranasally with either placebo or vaccine in a "double-blind" fashion in two doses, 2 weeks apart. Eighty-four subjects were challenged 30-100 days after the second dose with either the homologous or a heterologous strain. The heterologous strain for the A/Hong Kong/8/68 (H3N2) vaccinees was the A/England/42/72 (H3N2) virulent strain. The heterologous strain for the A/England/42/72 (H3N2) vaccinees was a virulent A/Dunedin/73 (H3N2) strain. Both vaccines led to good protection against both homologous and heterologous challenges. The protection rate against illness for the A/Hong Kong/8/68 (H3N2) vaccinees was 73% and 100% following homologous and heterologous challenges, respectively. The protection rate for the A/England/42/72 H3N2) vaccinees was 100% following both homologous and heterologous challenges. The protection rates against infection (as judged by antibody responses, irrespective of signs and symptoms) were also good. For the A/Hong Kong/8/68 (H3N2) vaccinees the rates were 73% (homologous) and 86% (heterologous). For the A/England/42/72 vaccinees, the rates were 72% and 60% respectively. Thus, immunity induced by these attenuated influenza vaccines extends to provide protection against related but non-identical influenza viruses.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0301-5149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
141-8
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:342305-Adult,
pubmed-meshheading:342305-Antibodies, Viral,
pubmed-meshheading:342305-Clinical Trials as Topic,
pubmed-meshheading:342305-Double-Blind Method,
pubmed-meshheading:342305-Female,
pubmed-meshheading:342305-Humans,
pubmed-meshheading:342305-Influenza A virus,
pubmed-meshheading:342305-Influenza Vaccines,
pubmed-meshheading:342305-Male,
pubmed-meshheading:342305-Nasal Mucosa,
pubmed-meshheading:342305-Therapeutic Irrigation,
pubmed-meshheading:342305-Vaccination,
pubmed-meshheading:342305-Vaccines, Attenuated
|
pubmed:articleTitle |
An attenuated influenza virus vaccine: protection against homologous and heterologous strains of virus.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|